Table 3 Hemodynamic data and circulatory support during the ICU stay
| Â | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 7 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Non-ECMO (n = 343) | ECMO (n = 35) | Non-ECMO (n = 325) | ECMO (n = 39) | Non-ECMO (n = 221) | ECMO (n = 24) | Non-ECMO (n = 184) | ECMO (n = 19) | Non-ECMO (n = 203) | ECMO (n = 16) | Non-ECMO (n = 187) | ECMO (n = 19) | |
Highest temperature (°C) | 37.3 (0.8) | 37.1 (1) | 37.2 (0.8) | 36.9 (0.9) | 37.1 (0.8) | 36.9 (0.7) | 37.1 (0.8) | 36.9 (0.8) | 37.1 (0.8) | 36.8 (0.8) | 37.1 (0.8) | 36.8 (0.9) |
Glasgow coma score (GCS) | 12.5 (4.5) | 7.5 (5.7) | 10 (5.3) | 8.6 (4.9) | 11.6 (5.1) | 6.75 (5.4) | 10.2 (6.1) | 6.5 (4.8) | 10.8 (4.4) | 6.7 (4.3) | 10.8 (5.4) | 6.6 (4.9) |
Mean arterial pressure (MAP) (mmHg) | 83.7 (14.9) | 84.9 (14.8) | 84.4 (13.9) | 83.6 (15.3) | 83.9 (14.1) | 86.3 (15.1) | 84.1 (14.7) | 86.6 (15.5) | 84.6 (13.4) | 87.9 (14.5) | 83.7 (13.9) | 83.8 (16.5) |
Use of epinephrine | 11 (3.2%) | 3 (8.6%) | 9 (2.8%) | 3 (7.7%) | 8 (3.6%) | 2 (8.3%) | 6 (3.3%) | 3 (15.8%) | 10 (4.9%) | 4 (25%) | 12 (6.4%) | 3 (15.8%) |
Maximum dose (mcg/kg/min) | 0.3 (0.3) | 0.1 (0.05) | 0.2 (0.1) | 0.2 (0.1) | 0.7 (0.1) | 0.3 (0.4) | 0.6 (0.9) | 0.4 (0.4) | 3.9 (9.4) | 0.3 (0.2) | 1.7 (2.8) | 0.3 (0.3) |
Use of norepinephrine | 178 (51.9%) | 29 (82.8%) | 183 (56.3%) | 34 (87.2%) | 194 (87.8%) | 23 (95.8%) | 162 (88%) | 14 (73.7%) | 168 (82.7%) | 13 (81.2%) | 155 (82.9%) | 17 (89.5%) |
Maximum dose (mcg/kg/min) | 2.4 (3.5) | 0.9 (1.9) | 0.6 (1.3) | 0.9 (1.7) | 0.84 (1.4) | 1.6 (1.9) | 0.7 (1.3) | 1 (1.6) | 0.9 (1.8) | 1.1 (1) | 0.9 (1.8) | 1.3 (1.9) |
Use of dopamine | 24 (7%) | 1 (2.8%) | 20 (6.1%) | 1 (2.6%) | 19 (8.6%) | 2 (8.3%) | 16 (8.7%) | 0 | 18 (8.9%) | 1 (6.2%) | 14 (7.5%) | 0 |
Maximum dose (mcg/kg/min) | 9.2 (6.3) | 5 (0.0) | 7.5 (6.7) | 5 (0.0) | 8.3 (6.7) | 5 (0.0) | 6.3 (5.1) | 0 | 6.2 (4.4) | 6 (0.0) | 6.5 (5.5) | 0 |
Use of dobutamine | 14 (4.1%) | 3 (8.6%) | 11 (3.4%) | 3 (7.7%) | 6 (2.7%) | 1 (4.2%) | 4 (2.2%) | 1 (5.3%) | 3 (1.5%) | 1 (6.2%) | 3 (1.6%) | 0 |
Maximum dose (mcg/kg/min) | 5 (0.0) | 3 (1.7) | 6.7 (2.9) | 2 (0.0) | 5.4 (2.7) | 2 (0.0) | 7 (2.4) | 2 (0.0) | 6.2 (1.2) | 2 (0.0) | 6.2 (1.2) | 0 |
Use of phenylephrine | 29 (8.4%) | 3 (8.6%) | 21 (6.5%) | 2 (5.1%) | 9 (4.1%) | 0 | 8 (4.3%) | 1 (5.3%) | 10 (4.9%) | 1 (6.2%) | 8 (4.3%) | 1 (5.3%) |
Maximum dose (mcg/kg/min) | 3 (3.3) | 4.3 (4.2) | 1.3 (0.7) | 1.6 (1.9) | 1.2 (1.9) | 0 | 5.8 (4.3) | 3 (0.0) | 2.7 (2.9) | 3 (0.0) | 2 (2) | 3 (0.0) |
| Â | Day 9 | Day 11 | Day 13 | Day 15 | Day 17 | Day 19 | Day 21 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Non-ECMO (n = 143) | ECMO (n = 23) | Non-ECMO (n = 133) | ECMO (n = 22) | Non-ECMO (n = 128) | ECMO (n = 18) | Non-ECMO (n = 95) | ECMO (n = 20) | Non-ECMO (n = 83) | ECMO (n = 20) | Non-ECMO (n = 63) | ECMO (n = 20) | Non-ECMO (n = 57) | ECMO (n = 20) | |
Highest temperature (°C) | 37.1 (0.8) | 36.8 (0.7) | 37.1 (0.8) | 36.9 (0.9) | 37 (0.7) | 36.9 (0.8) | 37.1 (0.7) | 37 (0.9) | 37.1 (0.7) | 36.9 (1) | 37.1 (0.8) | 36.8 (0.8) | 37.1 (0.7) | 36.9 (0.8) |
Glasgow coma score (GCS) | 9.8 (4.4) | 6.1 (4.7) | 9.1 (5.1) | 5.6 (3.7) | 8.6 (4.7) | 4.8 (4.1) | 8.9 (5.1) | 5.3 (4.8) | 7.6 (4.9) | 5.1 (4.4) | 7.1 (4.4) | 4.8 (3.9) | 6.7 (5.1) | 4.3 (3.1) |
Mean arterial pressure (MAP) (mmHg) | 83.2 (14) | 86.8 (16.1) | 81.8 (14.7) | 82 (12.9) | 81.8 (15.7) | 84.6 (13) | 81.3 (14.1) | 84.3 (12.8) | 80.9 (13.8) | 82.1 (13.9) | 81.8 (14.5) | 79.8 (14) | 80.1 (14) | 79.9 (17) |
Use of epinephrine | 9 (6.3%) | 6 (26.1%) | 4 (3%) | 4 (18.2%) | 8 (6.2%) | 3 (16.7%) | 4 (4.2%) | 4 (20%) | 3 (3.6%) | 3 (15%) | 1 (1.6%) | 3 (15%) | 3 (5.3%) | 3 (15%) |
Maximum dose (mcg/kg/min) | 0.9 (0.7) | 0.8 (0.2) | 1.8 (1.3) | 0.4 (0.4) | 0.3 (0.3) | 0.1 (0.05) | 0.9 (0.2) | 0.2 (0.2) | 0.5 (0.6) | 5.5 (9.1) | 1 (0.0) | 0.5 (0.4) | 0.6 (0.4) | 0.3 (0.2) |
Use of norepinephrine | 130 (90.9%) | 19 (82.6%) | 124 (93.2%) | 17 (77.3%) | 113 (88.3%) | 15 (83.3%) | 83 (87.4%) | 16 (80%) | 74 (89.1%) | 16 (80%) | 55 (87.3%) | 17 (85%) | 51 (89.5%) | 16 (80%) |
Maximum dose (mcg/kg/min) | 0.3 (0.5) | 0.3 (0.3) | 0.7 (1.3) | 1 (1.9) | 0.7 (1.7) | 0.33 (0.1) | 0.2 (0.3) | 1 (1.9) | 0.4 (0.5) | 0.3 (0.3) | 0.4 (0.6) | 0.3 (0.4) | 0.3 (0.5) | 0.5 (0.5) |
Use of dopamine | 6 (4.2%) | 0 | 3 (2.2%) | 1 (4.5%) | 6 (4.7%) | 0 | 6 (6.3%) | 0 | 6 (7.2%) | 0 | 4 (6.3%) | 0 | 2 (3.5%) | 0 |
Maximum dose (mcg/kg/min) | 5.9 (6.9) | 0 | 8.7 (9.8) | 2 (0.0) | 6.9 (7.3) | 0 | 3.9 (0.6) | 0 | 4.9 (3) | 0 | 4.1 (0.9) | 0 | 3.5 (1.5) | 0 |
Use of dobutamine | 1 (0.7%) | 1 (4.3%) | 2 (1.5%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1.6%) | 0 | 0 | 0 |
Maximum dose (mcg/kg/min) | 7.5 (0.0) | 1 (0.0) | 2.7 (0.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 (0.0) | 0 | 0 | 0 |
Use of phenylephrine | 4 (2.8%) | 1 (4.3%) | 6 (4.5%) | 2 (9.1%) | 4 (3.1%) | 1 (5.5%) | 4 (4.2%) | 0 | 3 (3.6%) | 1 (5%) | 3 (4.8%) | 1 (5%) | 3 (5.3%) | 1 (5%) |
Maximum dose (mcg/kg/min) | 3.2 (0.3) | 2 (0.0) | 0 | 2 (1.4) | 3.5 (3.5) | 0.8 (0.0) | 1 (0.0) | 0 | 1.1 (0.1) | 1.5 (0.0) | 1 (0.0) | 3 (0.0) | 0.7 (0.4) | 3 (0.0) |